



COVID-19 Vaccine Additional Doses for Immunocompromised Individuals Pharmacy Billing Guidance

On August 13, 2021, the Advisory Committee on Immunization Practices (ACIP) met and recommended an additional dose for immunocompromised individuals who have received the Pfizer-BioNTech or Moderna COVID-19 vaccine.

For all Plans covering COVID-19 vaccine administration under the pharmacy benefit, Providers must submit additional dose claims for immunocompromised individuals covered by these Plans with a Submission Clarification Code (SCC) (NCPDP field 42Ø-DK) value of "Ø7".

Providers should note that, per the Emergency Use Authorization (EUA), the additional dose for immunocompromised individuals should be administered at least 28 days following the first two doses of the vaccine.

When submitting claims for additional doses of COVID-19 Vaccine, the Provider must document how the Eligible Person meets the criteria to receive an additional dose. This may be in the form of an attestation from the Eligible Person (which should be noted by the pharmacist when the attestation is received verbally) or may also include documentation of the Eligible Person's qualifying condition or therapy in an accessible paper or electronic record. All documentation to support the administration of an additional dose must be retrievable for audit purposes.